Buchumschlag

Obituary for a diagnosis: B‐cell prolymphocytic leukaemia (1974–2022)

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Stephen P. Hibbs, Matthew L. Smith, Deborah Swinglehurst
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	HemaSphere
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Examining the secret life of the spleen in sickle cell disease
von: Adama Ladu, et al.
Veröffentlicht: (2025)

De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria
von: Peter Johnstone, et al.
Veröffentlicht: (2025)

Know your blood: Addressing barriers to preconceptual screening for sickle cell disease
von: Ernel Boadi, et al.
Veröffentlicht: (2025)

“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
von: Shoshana Burke, et al.
Veröffentlicht: (2025)

When to stop: Transfusions, difficult conversations and creativity
von: Sophie Evans, et al.
Veröffentlicht: (2024)

Informed consent is almost impossible
von: Louise Caldwell, et al.
Veröffentlicht: (2024)

Cellular therapies for sickle cell disease: Should we be calling them a cure?
von: Lydia O. Okoibhole, et al.
Veröffentlicht: (2025)

Can health inequalities in sickle cell disease be addressed through novel therapies?
von: Stephen P. Hibbs, et al.
Veröffentlicht: (2025)

Choosing words wisely: Language, metaphor, and psychological challenges after pulmonary embolism
von: Gerard Gurumurthy, et al.
Veröffentlicht: (2025)

Medical haematology trial eligibility and the Duffy null‐associated neutrophil count: A cross‐sectional study
von: Olga Tsiamita, et al.
Veröffentlicht: (2025)

Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up
von: Catherine Thieblemont, et al.
Veröffentlicht: (2025)

Correction to “Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up”
Veröffentlicht: (2025)

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma
von: Maeve A. O'Reilly, et al.
Veröffentlicht: (2024)

Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up
von: Francesco d'Amore, et al.
Veröffentlicht: (2025)

Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting
von: Katherine Antel, et al.
Veröffentlicht: (2026)

Diagnosis without consent: A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
von: Richard J. Buka
Veröffentlicht: (2026)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
von: Sophia Stock, et al.
Veröffentlicht: (2025)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
von: Daniel Mazza Matos
Veröffentlicht: (2026)

Lower efficacy of transfusion of red blood cells from donors with sickle cell trait
von: Monika Dzieciatkowska, et al.
Veröffentlicht: (2026)

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
von: Gloria Iacoboni, et al.
Veröffentlicht: (2024)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
von: Maeve A. O'Reilly, et al.
Veröffentlicht: (2024)

Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK
von: Andrea Kuhnl, et al.
Veröffentlicht: (2026)

Biomarker‐adapted treatment in high‐risk large B‐cell lymphoma
von: Sirpa Leppä, et al.
Veröffentlicht: (2025)

Accurate diagnosis of hemoglobinopathies with machine learning based on high‐throughput proteomics
von: Shaodong Wei, et al.
Veröffentlicht: (2025)

Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
von: Mariana Bastos‐Oreiro, et al.
Veröffentlicht: (2025)

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up
von: Andrés J. M. Ferreri, et al.
Veröffentlicht: (2024)

T‐cell lymphoblastic lymphoma in constitutional mismatch repair deficiency (CMMRD): Exploring treatment opportunities
von: Emma Kroeze, et al.
Veröffentlicht: (2024)

Outcomes and treatment patterns of patients with primary mediastinal B‐cell lymphoma after CAR‐T cell therapy failure: A DESCAR‐T analysis
von: Jean Galtier, et al.
Veröffentlicht: (2025)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
von: Rebeqa Gunnarsson, et al.
Veröffentlicht: (2025)

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
von: André Airosa Pardal, et al.
Veröffentlicht: (2025)

Delving deeper into the pathogenesis and genomics of posttransplant diffuse large B‐cell lymphoma
von: Flore Sneyers, et al.
Veröffentlicht: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
von: Mwanasha H. Merrill, et al.
Veröffentlicht: (2025)

Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL
von: Alfredo Rivas‐Delgado, et al.
Veröffentlicht: (2024)

TWIST2 high expression defines a novel subtype of B‐cell precursor acute lymphoblastic leukemia
von: Tao Zeng, et al.
Veröffentlicht: (2026)

Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
von: Jean Galtier, et al.
Veröffentlicht: (2025)

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group
von: Pierre Sesques, et al.
Veröffentlicht: (2026)

Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
von: Inna Y. Gong, et al.
Veröffentlicht: (2024)

Circulating tumor‐associated and neoantigen‐specific endogenous T cells in children treated for B‐acute lymphoblastic leukemia
von: Eliane Huwiler, et al.
Veröffentlicht: (2025)

Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across Europe
von: Florence Broussais, et al.
Veröffentlicht: (2025)

Machine learning enhances risk stratification and treatment failure prediction in diffuse large B‐cell lymphoma
von: Mikkel Werling, et al.
Veröffentlicht: (2026)